Zymergen (ZY) versus Its Competitors Financial Analysis

Zymergen (NASDAQ:ZYGet Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Zymergen to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, profitability, valuation and earnings.

Institutional and Insider Ownership

48.8% of Zymergen shares are owned by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 10.6% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Zymergen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zymergen -2,160.81% -213.99% -64.50%
Zymergen Competitors -255.16% -16.00% -2.18%

Earnings & Valuation

This table compares Zymergen and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Zymergen $16.74 million -$361.79 million -0.23
Zymergen Competitors $2.79 billion $101.13 million 22.95

Zymergen’s rivals have higher revenue and earnings than Zymergen. Zymergen is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zymergen and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymergen 3 5 0 0 1.63
Zymergen Competitors 98 739 1292 30 2.58

Zymergen presently has a consensus price target of $7.08, indicating a potential upside of 217.64%. As a group, “Commercial physical research” companies have a potential upside of 24.55%. Given Zymergen’s higher possible upside, equities analysts clearly believe Zymergen is more favorable than its rivals.


Zymergen rivals beat Zymergen on 11 of the 12 factors compared.

About Zymergen (Get Rating)

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.

Receive News & Ratings for Zymergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymergen and related companies with MarketBeat.com's FREE daily email newsletter.